NCT04432142View on ClinicalTrials.gov

Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

July 1, 2024

Study Completion Date

December 1, 2025

Conditions

Carcinoma, Non-Small-Cell Lung

Trial Locations (1)

6229 ET

Maastricht Radiation Oncology (MAASTRO clinic), Maastricht

All Listed Sponsors

lead

Maastricht Radiation Oncology

OTHER

NCT04432142 - Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial | Biotech Hunter | Biotech Hunter